Altimmune, Inc. 8-K Filings

Altimmune, Inc. reported second quarter 2026 results and a business update centered on its lead candidate pemvidutide for serious liver diseases. The company highlighted initiation of the global PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), positive topline Phase 2 data in alcohol use disorder (AUD), and completion of enrollment in the RESTORE Phase 2 trial in alcohol-associated liver disease (ALD). Pemvidutide holds FDA Fast Track designations for MASH and AUD and Breakthrough Therapy Designation for MASH.

As of June 30, 2026, Altimmune held $519 million in cash, cash equivalents and investments, providing substantial funding for ongoing trials. Total assets were about $527.2 million and stockholders’ equity about $474.2 million. For the quarter, Altimmune generated no revenue and recorded a net loss of $22.8 million, with research and development expense of $18.7 million and general and administrative expense of $7.6 million$45.4 million. Weighted-average basic and diluted shares outstanding for the quarter were 185.4 million, reflecting a significant increase in the share count compared with the prior year.

Altimmune reported positive topline Phase 2 results for once-weekly pemvidutide 2.4 mg in patients with moderate to severe alcohol use disorder. The study met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week versus placebo and achieved multiple secondary endpoints, including a two-level reduction in World Health Organization Risk Drinking Levels, zero heavy drinking days and reductions in phosphatidyl ethanol, an objective biomarker of alcohol intake; the first two are recognized by the FDA as registrational endpoints.

Pemvidutide showed a generally favorable safety and tolerability profile, with gastrointestinal adverse events such as nausea, vomiting, diarrhea and constipation more frequent than placebo but mostly mild to moderate in severity, and similar overall treatment discontinuation rates between arms. Altimmune plans to request an End-of-Phase 2 meeting with the FDA, submit the results for scientific presentation and publication, and continue developing pemvidutide across alcohol use disorder and serious liver diseases.

Altimmune, Inc. reported that it plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year. The company describes the new area as a strong biopharmaceutical hub that it expects will support recruiting top-tier talent within its hybrid work model.

Altimmune has signed an office lease for the New Jersey headquarters, under which it will pay approximately $300,000 in rent annually over a 5-year lease term. The company states that the headquarters move is expected to help achieve cost efficiencies over the long term, while it continues its growth as a late-stage development company.

Altimmune, Inc. reported first quarter 2026 results and a business update focused on its lead drug pemvidutide for serious liver diseases. For the three months ended March 31, 2026, the company generated no revenue, recorded operating expenses of $24.2 million, and reported a net loss of $22.6 million (basic and diluted net loss per share of $0.18), compared with a net loss of $19.6 million a year earlier.

Cash, cash equivalents and restricted cash were $97.6 million and short-term investments were $233.9 million as of March 31, 2026, and the company highlighted total cash, cash equivalents and short-term investments of $535 million as of April 30, 2026 following a recent financing. Total assets were $335.6 million and stockholders’ equity was $284.0 million as of March 31, 2026, with 130,221,154 common shares issued and outstanding.

Altimmune plans to initiate the PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2026, and expects topline Phase 2 data in alcohol use disorder (AUD) and enrollment completion in the RESTORE Phase 2 alcohol-associated liver disease (ALD) trial this year. Pemvidutide holds FDA Fast Track designations for MASH and AUD, and Breakthrough Therapy Designation for MASH.

Altimmune, Inc. completed an underwritten public offering of 64,250,000 shares of common stock at $3.00 per share, each sold with an accompanying common stock warrant. The company also issued, in lieu of shares to certain investors, pre-funded warrants to purchase up to 10,750,000 shares at $2.999 per pre-funded warrant.

Altimmune expects net proceeds of approximately $211.2 million, to be used with existing cash to advance clinical development of pemvidutide, including preparation for a global pivotal Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), to begin pre-commercial activities for its lead program, and for general corporate purposes.

Each common stock warrant is exercisable at $3.00 per share and remains exercisable until the earlier of five years from issuance or 45 days after a successful Phase 3 pemvidutide MASH data readout, subject to Beneficial Ownership Limitations generally at 4.99% or 9.99%, up to 19.99%. Pre-funded warrants have a $0.001 exercise price, do not expire, and also carry a 9.99% ownership cap, adjustable up to 19.99%.

Altimmune, Inc. reported results from its 2026 Annual Meeting and a key charter change. Stockholders approved an amendment to increase authorized common shares from 200,000,000 to 400,000,000, giving the company more capacity to issue stock in the future.

As of March 13, 2026, 130,105,177 shares were outstanding and entitled to vote, with 88,270,365 shares represented, a 67.8% quorum. Stockholders elected all director nominees, ratified Ernst & Young LLP as auditor, approved the advisory say-on-pay vote, expanded the 2019 Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares, and authorized potential adjournment of the meeting to solicit additional proxies.

Altimmune, Inc. reported 2025 results showing it remains a late-stage clinical biopharma focused on pemvidutide for serious liver diseases. For 2025, the company recorded a net loss of $88.1 million, improving from $95.1 million in 2024, as research and development spending fell to $66.4 million from $82.2 million. General and administrative expenses rose to $28.1 million from $21.0 million. Net loss per share narrowed to $1.00 from $1.34, on higher weighted-average shares.

Altimmune ended 2025 with $274.0 million in cash, cash equivalents and short-term investments and subsequently strengthened its balance sheet with a $75 million registered direct offering in January 2026 and a noncurrent term loan of $34.3 million. The lead asset pemvidutide received FDA Breakthrough Therapy Designation for MASH and Fast Track designations for MASH and AUD. The company plans to initiate a Phase 3 MASH trial in 2026 and expects topline data from its Phase 2 pemvidutide trial in alcohol use disorder in the third quarter of 2026, while a Phase 2 trial in AUD and the RESTORE trial in alcohol-associated liver disease continue.

Altimmune, Inc. has scheduled its 2026 Annual Meeting of Stockholders for Thursday, April 16, 2026, aligning its meeting timing with the typical second-quarter calendar for companies with a December 31 fiscal year-end. Stockholders of record at the close of business on Friday, March 13, 2026 will be entitled to receive notice of and vote at the meeting.

The exact time and location will be detailed in the company’s proxy statement, and the meeting is expected to be held virtually, similar to prior years. Stockholder proposals under Rule 14a-8 must reach the Company’s Secretary at its Gaithersburg, Maryland headquarters by February 13, 2026 to be considered for inclusion in the proxy materials.

Under Altimmune’s bylaws, any other stockholder proposals or director nominations for consideration at the 2026 Annual Meeting must also be received by the Corporate Secretary no later than February 13, 2026 and must meet bylaw requirements. Stockholders intending to solicit proxies for alternative director nominees under the universal proxy rules must provide the required notice by February 15, 2026 in accordance with the bylaws and Rule 14a-19.

Altimmune, Inc. entered into a securities purchase agreement with a new institutional investor for a registered direct offering of common stock and pre-funded warrants expected to raise approximately $75 million in gross proceeds.

The investor will purchase 12,397,920 shares of common stock and pre-funded warrants to buy up to 4,647,534 additional shares at a nominal $0.001 exercise price per warrant. The pre-funded warrants are immediately exercisable, do not expire, and are subject to a beneficial ownership cap starting at 9.99%, which can be increased up to 19.99% with notice. Directors and executive officers agreed to 30-day lock-up restrictions after closing.

Altimmune, Inc. established a new at-the-market equity offering program, allowing it to sell shares of common stock, from time to time at its sole discretion, for up to $200.0 million through Leerink Partners LLC as sales agent. Sales may be made on Nasdaq or other trading markets under an effective Form S-3 and related prospectus supplement, with a sales agent commission of up to 3.0% of gross proceeds.

The company also terminated its prior at-the-market facility, which authorized up to $150.0 million in sales through multiple agents. The new agreement contains customary terms, including indemnification and conditions, and does not require funds to be placed in escrow.

Altimmune, Inc. amended its loan agreement with Hercules Capital, increasing total term loan availability from $100.0 million to $125.0 million.

The facility provides up to four tranches: the first tranche of $15.0 million was drawn on May 13, 2025; the second tranche of $20.0 million was drawn at the November 5, 2025 amendment closing. A third tranche of up to $10.0 million becomes available upon achieving specified milestones, and a fourth tranche of up to $80.0 million is subject to lender approval.

The amended term loan bears interest at the greater of 9.70% per annum or the WSJ prime rate + 2.45%. The interest‑only period was extended to 30 months from May 13, 2025, which delays principal amortization. Altimmune also furnished a press release announcing third‑quarter results ended September 30, 2025.

Altimmune, Inc. reported a planned leadership transition in its medical organization. Former Chief Medical Officer Dr. Scott Harris has entered into a Transitional Services and Release Agreement and stepped down from the CMO role effective October 1, 2025, becoming Senior Strategic Advisor through his previously announced retirement date of February 28, 2026. The company has appointed Christophe Arbet-Engels, MD, PhD as the new Chief Medical Officer, effective October 1, 2025.

During the transition period, Dr. Harris will help transfer responsibilities and continue as an employee, receiving his current salary and benefits, continued vesting of outstanding equity awards through the separation date, an extension of his stock option exercise period to 12 months after separation, and eligibility for a full 2025 cash bonus, all conditioned on a release of claims and compliance with customary covenants.

Altimmune, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on September 25, 2025. As of the August 12, 2025 record date, 88,257,253 common shares were outstanding and entitled to vote. A total of 51,688,116 shares were present in person or by proxy, representing 58.6% of the voting power and establishing a quorum.

Stockholders elected all nominated directors, including Chairman Jerome Durso and Chief Executive Officer Vipin K. Garg, Ph.D., with each nominee receiving more votes “for” than “withheld.” Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2025, with 48,959,891 votes for, 1,355,769 against and 1,372,456 abstentions.

In an advisory “say-on-pay” vote, stockholders approved the compensation of Altimmune’s named executive officers, with 14,885,881 votes for, 6,683,682 against and 267,424 abstentions, plus 29,851,129 broker non-votes. Stockholders also approved a proposal to authorize possible adjournment of the meeting to allow additional proxy solicitation, with 33,695,815 votes for, 16,363,206 against and 1,629,095 abstentions.

Altimmune, Inc. filed a current report to furnish a press release announcing its financial results for the second quarter ended June 30, 2025. The press release, dated August 12, 2025, is included as Exhibit 99.1 and is provided for informational purposes rather than being formally filed under securities laws.

Altimmune (Nasdaq: ALT) filed an 8-K reporting positive topline data from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).

• MASH resolution without fibrosis worsening reached 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001).
• Histologic fibrosis improvement (31.8%/34.5% vs 25.9% placebo) was not significant, but AI analysis showed ≥60% fibrosis reduction in 30.6% at 1.8 mg vs 8.2% placebo (p<0.001).
• Mean weight loss 5.0%/6.2% vs 1.0% placebo (p<0.001); liver fat fell 58.0%/62.8% vs 16.2%.
• Safety: 0–1.2% AE-related discontinuations; no drug-related SAEs.

Slides (Ex 99.2) accompany a call on 26 Jun 2025. Forward-looking statements cite regulatory, trial and funding risks.